Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

BeOne Medicines (BEIGF) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for BeOne Medicines (BEIGF) over the last 11 years, with Q3 2025 value amounting to 11.55%.

  • BeOne Medicines' EBITDA Margin rose 235600.0% to 11.55% in Q3 2025 from the same period last year, while for Sep 2025 it was 3.67%, marking a year-over-year increase of 299800.0%. This contributed to the annual value of 14.91% for FY2024, which is 342100.0% up from last year.
  • Latest data reveals that BeOne Medicines reported EBITDA Margin of 11.55% as of Q3 2025, which was up 235600.0% from 6.68% recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' EBITDA Margin ranged from a high of 89.06% in Q4 2021 and a low of 316.58% during Q2 2021
  • Over the past 5 years, BeOne Medicines' median EBITDA Margin value was 34.77% (recorded in 2024), while the average stood at 63.67%.
  • As far as peak fluctuations go, BeOne Medicines' EBITDA Margin surged by 7295300bps in 2021, and later tumbled by -2123500bps in 2022.
  • Quarter analysis of 5 years shows BeOne Medicines' EBITDA Margin stood at 89.06% in 2021, then plummeted by -238bps to 123.29% in 2022, then skyrocketed by 51bps to 60.5% in 2023, then soared by 88bps to 7.04% in 2024, then soared by 264bps to 11.55% in 2025.
  • Its EBITDA Margin was 11.55% in Q3 2025, compared to 6.68% in Q2 2025 and 0.99% in Q1 2025.